COVID-19: Indofarma to Produce Ivermectin in July



Markus Wisnu Murti

  • Font:
  • Ukuran Font: - +
  • Ivermectin. Brazilian Report

    Ivermectin. Brazilian Report

    TEMPO.CO, Jakarta - State-owned pharmaceutical firm PT Indofarma on Friday spoke about Ivermectin that has recently claimed popularity after a number of public figures claimed the drug's effectiveness against COVID-19. 

    Asked by Tempo about the price for one pack, Indofarma management stated in a written release on Friday, July 2, that they “established the price for [Ivermectin] at Rp123 thousand.”

    The product they sell includes 20 tablets of 12 mg per botol. The highest retail price that includes the added-value tax (PPN) is set at Rp157,700 (US$10 in current exchange). 

    Based on Tempo’s observation across online and physical stores the drug is sold at an average price of Rp200,000 (US$13.7) with the highest retail price at Rp256,000 (US$ 17). 

    Ivermectin, as of June 20, has obtained marketing authorization from the Food and Drugs Monitoring Agency (BPOM). Indofarma stated the production of the drug would kickstart in early July, and that it aimed at producing 13.8 million tablets until August 2021. 

    Read: Ivermectin as COVID-19 Treatment to Be Priced at Rp5,000-7,000 per Tablet